Arrowhead Research News Today

Pressure we saw on the dow all morning has leavitted. The industrial average is up 25 points, although the nasdaq struggling to stay positive. Early selling gave way to some buying in the afternoon, once again. Yeah. An upanddown day and a big week for economic news. We have the jobs report on friday. Before that, on wednesday, we get fed day. Amid word of growing descent among hawkish members of Janet Yellens gang. Well talk about that with jim grant in a little bit. Plus, the tax inversion deb...

/PRNewswire/ -- The Global Small Interfering RNA (SiRNA) Market size is projected to be $964.17 Million by 2030 growing at a CAGR of 8.6% from 2023 to 2030, as...

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Arrowhead Research Corp. (ARWR) on Monday reported a loss of $41.3 million in its fiscal first quarter. On a per-share basis, the Pasadena, California-based company said it had a loss of 39 cents.

Dublin, July 15, 2022 (GLOBE NEWSWIRE) -- The "Global Nanomedicine Market (2022-2027) by Indication, Drug Delivery System, Product, Application,...

/PRNewswire/ -- The "Global Nanomedicine Market (2022-2027) by Indication, Drug Delivery System, Product, Application, Geography, Competitive Analysis, and the...

/PRNewswire/ -- The "Global Nanomedicine Market (2022-2027) by Indication, Drug Delivery System, Product, Application, Geography, Competitive Analysis, and the...

PASADENA, Calif. (AP) _ Arrowhead Research Corp. (ARWR) on Tuesday reported fiscal second-quarter net income of $44.4 million, after reporting a loss in the same period a year earlier. The Pasadena, California-based company said it had net income of 41 cents per share.

Arrowhead Research: Fiscal Q2 Earnings Snapshot May 4, 2021 FacebookTwitterEmail PASADENA, Calif. (AP) _ Arrowhead Research Corp. (ARWR) on Tuesday reported a loss of $26.8 million in its fiscal second quarter. On a per-share basis, the Pasadena, California-based company said it had a loss of 26 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share. The drug developer posted reven...